All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 22, 2022
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Hand holding lightbulb

Startup Somne collars new solution for treating obstructive sleep apnea

Sep. 16, 2021
By David Godkin
No Comments
Newly launched startup Somne Inc. plans to give CPAP machines a run for their money by replacing CPAP masks and hoses for treating obstructive sleep apnea with a gentler collar encircling the patient’s neck. The new device uses variable negative pressure to ensure users get a good night’s sleep instead of positive airway pressure employed by companies such as Resmed Inc. and Philips Respironics Inc.
Read More
Digital cancer cells illustration
Newco news

Binhui moves HSV-2-based oncolytic viral candidate toward U.S. trial

Aug. 31, 2021
By Doris Yu
No Comments
Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA.
Read More
Central nervous system
Newco news

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

Aug. 31, 2021
By Nuala Moran
No Comments
LONDON – A significant body of research indicates inhibition of the mitochondrial permeability transition pore (PTP) would reduce neuroinflammation and protect neurons, but the difficulty of finding inhibitors that cross the blood-brain barrier to regulate the pore has left the therapeutic potential largely untapped.
Read More
Cancer cell and DNA
Newco news

Binhui moves HSV-2-based oncolytic viral candidate toward U.S. trial

Aug. 30, 2021
By Doris Yu
No Comments
Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA. The development marks the first oncolytic viral candidate developed by a Chinese company to win a go-ahead for trials abroad, it said.
Read More
Hand holding money plant

Fluid Biotech raises $4.7M for a world’s first in brain stent development

Aug. 24, 2021
By David Godkin
No Comments
TORONTO – Fluid Biotech Inc. has raised $4.7 million in oversubscribed seed funding to further develop and commercialize the world's first hybrid polymer-metal flow-diverting brain stent for curing brain aneurysms that can lead to stroke. Following successful preclinical studies of the stent, attention now turns to applying this fresh capital to hiring contract manufacturers to prepare for first-in-human implantation and production of the mostly polymer-constructed stent.
Read More
Desk with computer monitor displaying Genieus' software

Genieus builds neurodegenerative diseases platform to develop diagnostics, personalized medicines

Aug. 12, 2021
By Tamra Sami
No Comments
PERTH, Australia – Bioinformatic and cell technology company Genieus Genomics Ltd. is using the power of the human genome to build a platform for neurodegenerative diseases to develop diagnostic tests for personalized medicines.
Read More
HIV infected cell
Newco news

Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out

Aug. 12, 2021
By Richard Staines
No Comments
Finding a functional cure to HIV is one of the biggest challenges in modern medicine, a task made so much tougher because of the virus’s ability to incorporate itself permanently into a host’s genome. But Diaccurate SAB, of Paris, thinks it may have a solution – and it’s all down to a discovery showing that the virus seems to make crucial immune CD4 cells go “bumpy”, lose their function and die.
Read More
Macrophage and cancer cell
Newco news

Macomics aiming to harness full potential of TAM biology

Aug. 9, 2021
By Nuala Moran
No Comments
LONDON – Newco Macomics Ltd. has closed its first financing round at £7.4 million (US$10.3 million), enabling it to lay the ground for a new approach to addressing immunosuppression in the tumor microenvironment by modulating disease-specific macrophages.
Read More
Coins and seedling
Newco news

Mestag targeting fibroblasts to tackle cancer, immune diseases

Aug. 6, 2021
By Nuala Moran
No Comments
LONDON – Mestag Therapeutics Ltd. has closed a hefty $45 million seed round to advance development of antibodies targeting activated fibroblasts, in the treatment of cancer and immune diseases.
Read More
Stem cells
Newco news

Hopstem targeting stroke with iPSC-derived human forebrain neural progenitor cell product

July 27, 2021
By Elise Mak
No Comments
With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 28 29 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 20.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
  • US FDA rejects UCB psoriasis drug Bimzelx, citing facility inspection issues

    BioWorld
    UCB SA’s share price slumped after the U.S. FDA rejected the pharma’s filing for psoriasis drug Bimzelx (bimekizumab), citing issues with “inspection...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing